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For many years, this section was 
a space for readers’ feedback 
to a particular issue, or story. 
It is still that, and will continue 
to be so long as the U.S. Postal 
Service delivers mail.
But there’s another world in 
which stories receive attention 
and feedback: online. And while 
Yale Medicine Magazine’s physi-
cal circulation is around 22,500, 
online it receives around 25,000 
unique visits per month. 
Editing Yale Medicine 
Magazine is my primary respon-
sibility, and both a joy and a 
privilege. I have a second job, 
though, which I created for 
myself: I plan, manage, and run 
Yale School of Medicine (YSM)’s 
social media accounts. As read-
ers are likely aware, social media 
is a proving-ground for ideas 
both small and great, and the 
social and scientific assertions 
and hypotheses of YSM faculty 
and researchers are no excep-
tion to that rule.
In the coming issues, we 
would like to offer up examples 
of conversations that happened 
online, that in the past may 
have made their way into this 
section via the postal service. 
These include posts on LinkedIn, 
Twitter, Facebook, or Instagram 
that the public found to be 
interesting or noteworthy.  
Or ideas that were sufficiently 
resonant to capture my attention.
The three posts for this 
issue that stood out were, 
first, that announcing Nancy 
Brown’s assumption of the 
deanship—our most read, 
shared, and commented-on 
post on LinkedIn of all time. The 
commentary was universally 
celebratory and positive in 
tone. Second, a post by Yale 
Orthopaedics commemorat-
ing International Women’s 
Day with a callout to Rosie the 
Riveter. Third and finally, a post 
by Interventional Radiology 
technicians in the Department 
of Radiology & Biomedical 
Imaging was shared by CNN’s 
Instagram page, where it 
received nearly a quarter of a 
million likes—a bit more than 
our more modest totals. 
Many other subjects find air 
on social media. These were 
the three that jumped out from 
within YSM’s community. To 
hop onboard a social media con-
versation, look us up online.
Adrian Bonenberger 
Editor, Yale Medicine Magazine
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Yale’s Actions and Response to Coronavirus (COVID-19) website, covid.yale.edu, provides  
such information as clinical and laboratory research, patient care, resources to both track  




  The road back  
 to New Haven
just weeks into her tenure as the 19th dean of Yale 
School of Medicine, Nancy J. Brown, MD, found herself 
thrust into the center of a global pandemic. She shared her 
thoughts with Yale recently on the state of the school, and 
its efforts to help turn the tide against COVID-19.
How have Yale School of Medicine doctors responded to the influx of 
patients with COVID-19? Our response to COVID-19 has brought out the 
caring, collegiality, and creativity of our people. Clinical leaders are 
working hard to ensure that we have personal protective equipment, 
sufficient capacity in the hospital, and enough clinicians. Clinical 
Virology Laboratory developed testing for COVID-19 in-house, and this 
has made rapid testing available for health care workers.
Our critical care physicians have stood up and equipped hospital 
floors dedicated to the care of COVID-19 patients, with more space 
on the way. To decrease the number of ambulatory patients, our fac-
ulty have greatly expanded telehealth services. Clinical leaders have 
conferred with colleagues throughout the world to learn from their 
experience and strengthen our response.
What research is taking place around the virus? Epidemiologists across 
the health science schools have been modeling the pandemic to allow 
us to focus resources where and when they are needed. Our world-
class immunologists have shifted their programs to understand how 
COVID-19 infects cells, the immune system’s response, and how to 
interrupt that process. Our geneticists are exploring how patient fac-
tors determine outcome. Data scientists study outcomes in patients 
using electronic health records. We are sharing these methods with 
other institutions to facilitate effective research, and are leverag-
ing the infrastructure of the Yale Center for Clinical Investigation to 
quickly initiate clinical studies of new therapies.
Other than moving to online classes, what is the effect on medical students?  
We had to interrupt the clinical clerkship training, which provides 
medical students with clinical experience. Students are valuable 
members of the care team, but with the decrease in ambulatory visits 
and elective surgeries, clerkships didn’t make sense. Students are 
working with their advisors to develop individually tailored plans. 
Many have volunteered to conduct literature searches for our teams, 
just as they would on the wards. The students also suggested creat-
ing an elective on COVID-19 and pandemics. This is a trying time, but 




















   Laying the  
  groundwork 
in december 2019, Merck received FDA approval for 
the Ebola vaccine trademarked Ervebo. Merck had dis-
tributed this vaccine for free in the Democratic Republic 
of the Congo over the last year and a half. The vaccine 
is based on a viral vector developed in the lab of John 
Rose, PhD, professor emeritus of pathology and senior 
research scientist in the Department of Pathology during 
an eight-year period in the 1990s. Rose is currently the 
director of Yale’s Molecular Virology Program. The Ebola 
vaccine based on Rose’s research has proven to be close to 
100% effective in preventing Ebola infection.
“It’s incredibly rewarding to 
know that one’s efforts have 
made a tangible difference in the 
world,” said Rose. “Merck has 
provided the vaccine for free to 
over 250,000 people.” 
Rose said that the proj-
ect started out as a method 
to develop a general vaccine 
platform for viruses and other 
pathogens. His lab’s work with 
this vaccine system focused 
initially on multiple viruses 
including HIV, a notoriously 
tricky and mutable foe. His 
laboratory also distributed the 
viral genetic system to over 100 
other labs, including the one 
that eventually developed the 
Ebola vaccine.
The method relies on genetic 
engineering of a relatively benign 
animal virus called vesicular 
stomatitis virus (VSV) to express 
protein antigens from dangerous 
viruses or other pathogens. This 
system can be used to generate 
vaccines against multiple threats. 
For example, it can even protect 
against plague caused by the 
Yersinia pestis bacterium. 
It can also protect against 
coronaviruses. Rose and col-
leagues published a paper in 
2005 demonstrating a VSV-
based vaccine that protects 
against SARS coronavirus in the 
wake of the SARS outbreak. 
“A VSV vector worked for 
SARS, so almost certainly will 
for other coronaviruses like 
the 2019-nCoV,” wrote Rose via 
email. “The recombinant vac-
cine could be made in a week, 
but approval for use could take 
ymm.yale.edu4
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years. SARS was contained 
through public health measures, 
long before a vaccine could be 
tested and approved.”
While the legal mechanisms 
by which different vaccines  
are tested and approved for use 
are endeavors in their own right 
apart from research, the news 
is good: if the current outbreak 
of coronavirus were to intensify 
dangerously, researchers  
would have little difficulty in 
creating vaccines. 
Vaccines for HIV and Zika 
using the VSV platform are still 
under development, but show 
great promise. And Rose is happy 
his team had an opportunity 
to work on a project of lasting 
importance. “The researchers 
who worked on this project are 
spread to the four winds, and 
many have their own labs now,” 
he said. “Knowing that we’ve 
made a significant contribution 
to humankind in terms of under-
standing how viruses work, and 
offering ways to combat them, is 
a very good feeling.”
—Adrian Bonenberger
»
Researching a  
clinical mystery
When Daniel Wong was over-
come by seizures that struck 
out of the blue only two 
months after he graduated from 
Stanford in 2013, his doctors 
were alarmed. They could find 
no triggering event, no history 
of epilepsy, no explanation for 
his sudden prolonged seizures. 
Electron micrographs of 
VSV particles, taken in 
the laboratory of John 
“Jack” Rose. They show 
(clockwise from above) 
the bullet-shaped “magic 
bullets” engineered to 
carry extra genes and 
make vaccines, an in-
fected animal cell where 
thousands of VSV par-
ticles are budding from 
the cell’s surface, and, 
finally, an enlargement 















































Yale School of 
Medicine researchers 
such as Christopher H. 
Gottschalk, MD, and 
Deena Kuruvilla, MD, 
are looking at ways to 
stop migraine. They’ve 
found that certain 
medications work 
on the inflammatory 
cascade that plays a 
role in producing of-
tentimes debilitating 
pain for the patient.
For more on migraine, 
visit ymm.yale.edu/
migraine
Information Center (GARD), 
the National Organization for 
Rare Disorders (NORD), and the 
Epilepsy Foundation. 
To build a common lan-
guage for the disorder, Hirsch 
assembled a group of interna-
tional experts to develop con-
sensus definitions of NORSE 
and a related syndrome termed 
FIRES (febrile infection-related 
epilepsy syndrome). “So far the 
NORSE Institute has developed, 
posted, and published a recom-
mended diagnostic evaluation 
for specialists, readily available 
through the NORSE Institute 
website,” said Hirsch. “One of 
the first challenges for a new 
disease is creating a name and 
consistent definition for it. The 
next is awareness—making sure 
everyone knows about the dis-
ease or the condition’s defini-
tion.” The NORSE Institute has 
been very successful in address-
ing these issues. 
Doctors placed the 22-year-old 
Daniel in a drug-induced coma 
to protect his brain and tried 
numerous therapies to control 
his seizures. All treatments 
failed. Less than three months 
later, Daniel died without 
regaining consciousness.
At the suggestion of one of 
his doctors, Daniel’s parents, 
Nora and Raymond Wong (both 
graduates of Yale College) met 
with Yale School of Medicine 
(YSM) neurologists Lawrence J. 
Hirsch, MD ’91; Emily J. Gilmore, 
MD; and Nicolas Gaspard, PhD, 
at Yale New Haven Hospital in 
August 2014. The clinicians were 
planning a multinational, multi-
center study to include patients 
like Daniel—who was thought to 
have a syndrome referred to as 
new-onset refractory status epi-
lepticus or NORSE.
NORSE is described as a  
clinical presentation of pro-
longed seizures that are 
uncontrolled by at least two 
antiseizure medications, with 
the cause of the seizures 
remaining unidentifiable 
for 72 hours. NORSE tends to 
affect primarily healthy young 
adults and children with no 
previous history of epilepsy. 
The consequences of the dis-
order are devastating. There 
is significant short-term 
mortality (as high as 27%) 
and morbidity. Patients often 
survive with significant brain 
damage and develop chronic 
epilepsy. The Wongs created 
the Daniel Raymond Wong 
Neurology Research Fund at 
YSM to support this prospec-
tive observational study that 
collects clinical data from 
NORSE patients and their bio-
specimens, both of which are 
banked at Yale.
With Hirsch and Gaspard 
as co-chairs of her medical 
advisory board, Nora Wong 
established the NORSE Institute 
(norseinstitute.org), a collabora-
tion of NORSE families, clini-
cians, and basic scientists. In 
the past five years, the NORSE 
Institute has worked to raise 
awareness of this rare disorder. 
At Nora’s request, Hirsch and 
Gaspard wrote the first descrip-
tion of NORSE issued on the rare 
disease websites hosted by the 
National Institutes of Health’s 





















Daily News as an undergrad. 
Mirza and Vijay make the first 
pass at story ideas that come in 
via email, at grand rounds, and 
through the grapevine.
Another YSM graduate who 
put heavy work into tracking 
down appropriate patient stories 
was Michael Gormally, MD ’19, 
PhD. “Michael helped me set up 
a system for me to keep track 
of the patients I am planning to 
write about,” said Sanders. “Not 
a week goes by that I don’t ben-
efit from his smart system.”
With the column’s increas-
ing popularity and the debut 
of the Netflix series in August, 
emails have poured in, Sanders 
said. “Right now, I get about 
100 emails a day. Before, I got 
maybe 100 a month.”
How do Sanders and her assis-
tants decide what makes the cut? 
First, there has to be a mystery.
Each column starts with 
symptoms ranging from the 
commonplace to the bizarre that 
stymie the patient’s doctor or 
doctors. They may order further 
tests or consult with colleagues 
as they seek a diagnosis. “You 
know it’s a weird case if it’s in 
my column,” Sanders said. 
“Often, it’s a very rare pre-
sentation of a common disease, 
and you want to look at some-
thing that has a happy ending,” 
said Mirza. “If it doesn’t have a 
happy ending, there’s some sort 
of big lesson you can take from it 
that can help other patients.”
“It’s easier to have a case 
when there is one team or one 
doctor that made the decision 
»
Behind the scenes at 
“Diagnosis”
Twice a month, the “Diagnosis” 
column appears in The New York 
Times Magazine. In 1,300 words, 
Lisa Sanders, MD ’97, HS ’00, 
associate professor of medicine 
at Yale School of Medicine (YSM), 
untangles a case that has had doc-
tors scratching their heads as they 
sort through a patient’s symp-
toms for clues to the diagnosis.
“I’m interested in the diag-
nostic process, how you get from 
puzzling symptoms to an 
important diagnosis,” said 
Sanders, who started writing 
the column in 2002. 
Since then her column has 
spawned a TV drama, House, 
which aired from 2004 to 2012; 
provided material for her own 
books; and recently became a 
series on Netflix. At first, the 
column appeared once a month 
and Sanders did all the research 
and interviews on her own. But 
in 2016, when her editor asked her 
for two columns a month, “I real-
ized I needed help,” Sanders said.
She turned to the Office of 
Student Affairs, which sent an 
email inviting medical stu-
dents to apply for an interesting 
research opportunity. Sanders’s 
first hire was Fatima Mirza, a 
third-year student, who wrote 
for the Harvard Crimson as an 
undergrad and served as co- 
editor-in-chief of the Yale 
Journal of Biology and Medicine. 
A year ago, Sanders took on a 
second assistant, Aishwarya 
Vijay, a fourth-year student at 
YSM, who wrote for the Yale 
“NORSE shares some attributes 
with FIRES, now defined as a 
subset of NORSE, in which the 
patient has a prior infection with 
fever, usually a mild one,” said 
Hirsch. He added that although 
FIRES has traditionally been asso-
ciated with children, it occurs in 
adults as well.
Through the Wongs’ support, 
the NORSE Institute sponsored 
the first international confer-
ence on NORSE in Salzburg, 
Austria, in 2017, where Hirsch 
and his group of experts met 
and later presented the consen-
sus definitions. The definitions 
were published in Epilepsia in 
2018 and are accepted as stan-
dard definitions worldwide. A 
roadmap of NORSE research 
was published in Neurology 
by Hirsch, Gaspard, and other 
members of the NORSE Institute 
medical advisory board. The 
institute sponsored multiple 
roundtable workshops with 
international researchers 
discussing the immunologic, 
genetic, and clinical aspects 
of NORSE, including ways to 
determine the best treatments. 
And in December 2019, the 
NORSE Family Registry was 
launched. This registry allows 
families to provide retrospec-
tive information about NORSE 
patients; it is intended to com-
plement the ongoing prospec-
tive study of acutely ill NORSE 
patients. The NORSE family reg-
istry is supported through a gift 
to Yale by the family of Robert N. 




Yale Journal of Biology 
and Medicine has, at 
long last, earned an 
Impact Factor. This 
means they’ll be 
monitored to see how 
often their articles 
are cited by others, a 
huge coup for the only 
internationally recog-
nized medical journal 
edited and published 
by students.
For more on YJBM, visit 
ymm.yale.edu/yjbm
and can really focus and give a 
full narrative,” Vijay added.
To find those cases, the team 
sorts through thousands of tips 
for the 24 that will make it into 
the column each year. Then 
they reach out to the doctor on 
a promising case and obtain a 
signed release to speak to the 
patient and obtain medical 
records. “Until you talk to them 
you never get the full story,” 
Mirza said. “You get a two- or 
three-sentence synopsis from 
their email and you don’t know 
if it’s a real diagnosis.”
The students then explain 
how the reporting and writ-
ing process will unfold. “The 
patients are usually ecstatic,” 
Vijay said. “They want to get 
the word out about what they 
struggled with.”
After initial interviews and 
a review of the medical records, 
Mirza and Vijay pass their sug-
gestions on to Sanders. And they 
note that there are often false 
starts. “Stories fall through all 
the time,” Vijay said. “We get 
halfway down the line and then 
the medical records don’t work 
out or the patient has decided 
that they don’t feel comfortable.”
The irregular schedules of 
medical students and a working 
physician, and the unyielding 
deadlines of a major newspaper 
make for odd working hours. 
Sanders and her two assistants 
are rarely able to meet in person, 
so they communicate by phone 
and email. And they’re usually 
multitasking. “We often have 
multiple cases and a bunch on 
the back burner,” said Vijay.
Once she’s chosen the cases for 
her column, Sanders reaches out 
to the patient and doctor for more 
in-depth interviews. There may 
be multiple doctors on the case, 
but Sanders usually interviews 
only the ones who made the diag-
nosis. Readers often ask how the 
doctors could have missed what 
seems in hindsight so obvious. 
“Diagnosis is a process,” 
Sanders said. “You have to go 
through what everybody has 
before you can look at what 
nobody has.”
Sanders typically spends two 
days on her first draft, then goes 
over it twice more. Her columns 
reach the Times on a Monday; by 
Thursday of the following week 
they’re online; and by the next 
Sunday they’re in print.
“When I see it in the paper,” 
she said, “I know it’s time to 




Due to underlying disease, esti-
mates of preventable deaths 
of hospitalized patients may be 
two to four times too high. The 
YSM and VA Connecticut study 
extrapolated likely numbers for 
the United States from results in 
European and Canadian hospitals. 
Benjamin Rodwin, MD, assistant 
professor of medicine, said that 
more studies are needed, but the 
notion that the quality of care in 
hospitals is better than previously 
assumed is indeed welcome news.
 MEDICAL ERRORS DON’T PLAY  
A ROLE IN MOST HOSPITAL DEATHS
A new alumni health group, co-
founded by Christine Walsh, 
MD ’73, and Jamie Wells, MD, held 
its inaugural meeting at the Yale 
Club of NYC this winter. The Yale 
Alumni Health Network (YAHN) 
hopes to bring Yale alumni lead-
ers together from all sectors that 
touch on health and health care: 
medical practice, academia, sci-
ence, law, and finance.
Interested Yale School of Medicine 
(YSM) alumni can find YAHN on 
Facebook, Twitter, and LinkedIn.
 BRIGHT START FOR YALE 
ALUMNI HEALTH NETWORK
A study co-authored by Yale soci-
ologist Grace Kao, PhD, concludes 
that first grade teachers’ racial and 
gender biases about the abilities of 
their students affects how those 
students perform academically, as 
well as how those students view 
themselves and their abilities.
Kao’s study was published online 
in January in the Du Bois Review: 
Social Science Research on Race. 
 SCHOOLCHILDREN SHAPED 
BY TEACHERS’ BIASES
According to the lead author of a 
recent study, the keto diet’s effec-
tiveness derives from its ability 
to trick the body into burning fat. 
Vishwa Deep Dixit, DVM, PhD, the 
Waldemar Von Zedwitz Professor 
of Comparative Medicine and pro-
fessor of immunology, evaluated 
the mechanisms by which the body 
processes different types of food—
in this particular case, a diet’s low 
carbohydrate content—and made 
the unusual discovery.
Dixit warns, however, that the 
keto diet works for only a limited 
time period in mice, and that stud-
ies in humans are needed to find 
out whether humans can safely fol-
low the diet for months or years.





























a collection of recent  
scientific findings

IN THIS ISSUE, Yale Medicine Magazine covers research at Yale School of 
Medicine that extends the boundaries of what humankind knows about 
inflammation—the body’s response to threat or infection. Our writers 
explore the long history of physicians observing inflammation and also de-
scribe the physiology of inflammation—what current science understands 
about the process of inflammation, its energy costs, and the role it plays 
in wound repair and aging. Finally, we attempt to lay out the most current 
progress being made in understanding why immune systems work the way 
they do. 
At stake is more than just the short-term benefits versus long-term 
costs of inflammation. Many diseases and conditions are either caused or 
influenced by malfunctioning immune systems—from lupus to Alzheimer’s 
disease to diabetes and many more. Understanding how the immune  
system works and the role inflammation plays will do more than answer 
esoteric questions about disease—it will improve the quality of life for 
people who are struggling every day with deadly ailments, and may even 
save or extend lives.
Inflammation: part hero, part villain 12
Studying autoimmunity 18
Ketostasis: nature’s sweet spot 20
Another use for aspirin 24
Untangling the web of autoimmune disorders 26
Why most heads don’t swell 30
A new dimension to intestinal surgery 34
Exploring the frontiers of immunity and healing 36
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Inflammation:  
part hero,  
part villain 

For many years, inflammation was considered one of 
medicine’s chief enemies. Experts viewed it as a side 
effect of illness and injury, a negative byproduct of the 
body’s efforts to heal. One managed and banished it 
whenever possible. 
That view has undergone a major reassessment  
over the last decade. Inflammation, it turns out,  
isn’t always bad. In fact, researchers increasingly 
believe that it plays a vital role in maintaining good 
health. Some even believe inflammation is so central 
to the body’s proper functioning that our under-
standing of physiology must be rewritten.
“It (inflammation) is a very natural state,” said 
David A. Hafler, MD, the William S. and Lois Stiles  
Edgerly Professor of Neurology, professor of 
immunobiology, and chair of the School of Medi-
cine’s Department of Neurology. “When you look  
at the immune system, it has multiple roles.  
The obvious one is fighting off infection. But the 
immune system has also been co-opted by nature  
to be used in a number of different systems for 
homeostasis. Inflammation is more than about just 
fighting off disease.”
Some examples: The immune system acts at times as 
a kind of cleanup crew that tidies up molecular messes. 
Elsewhere, it performs such functions totally unrelated 
to fighting microbes as pruning excess neurons in the 
brains of small children—an essential part of brain 
development. The immune system also helps regulate 
the function of many organs, including the liver and 
intestines. In doing all of these good things, it inevita-
bly leaves residual inflammation. 
a two-edged sword
While these insights recast inflammation as a more 
positive component of a person’s health, they  
also raise intriguing questions about how it may  
cause illness later in life. Are such diseases as  
cancer, for example, triggered when the immune  
system’s maintenance and regulatory duties go  
Inflammation: part hero, part villain
The traditional approach 
to inflammation is that 
it’s bad and should be 
suppressed, but recent 
findings offer a more 
nuanced view.
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awry, often in connection with a gene, and cause too 
much inflammation?
“The immune system is a two-edged sword,” said 
John MacMicking, PhD, an associate professor of micro-
bial pathogenesis and of immunobiology, and a Howard 
Hughes Medical Institute (HHMI) investigator. “Some 
things help protect you. Some things put you in harm’s 
way. Researchers are looking for the right balance.”
Inflammation has already been identified as a 
culprit instead of just a side effect in many illnesses, 
including multiple sclerosis (MS) and other autoim-
mune diseases. We have also learned that it plays a 
role in so-called lifestyle illnesses and such conditions 
as heart disease, obesity, and diabetes, said Akiko 
Iwasaki, PhD, the Waldemar Von Zedtwitz Professor 
of Immunobiology, professor of molecular, cellular 
and developmental biology, and an HHMI investiga-
tor. It’s hard to think of any disease that does not 
involve inflammation, Iwasaki said. That fact has some 
researchers calling for a wholesale reassessment of 
inflammation’s role in the body’s functioning. 
“We still think in terms of normal physiology and 
abnormal inflammation,” said the Sterling Professor 
of Immunobiology and HHMI investigator Ruslan 
Medzhitov, PhD, one of the world’s leading inflam-
mation researchers. “That view is, I think, outdated. 
There’s no modern framework to replace that view.”
Medzhitov and his lab are hard at work building 
that scaffolding. He argues that inflammation is as 
central to understanding physiology as are hormones. 
Once the initial work is complete, the next stage will 
be to try to find ways to turn inflammation on and off 
to treat or forestall disease, he said. He estimates we 
are about halfway to mapping the basics but only 10% 
of the way toward fully understanding how inflamma-
tion works.
“It’s clear that inflammation is not just about infection,” 
he said. “It’s not just a response to injury. It has multiple 
other job descriptions, multiple other functions that are 
involved also in what we call normal physiology.”
In a pioneering step, the medical school has 
incorporated Medzhitov’s findings into its cur-
riculum, teaching future doctors that inflammation 
is an integral part of both health and sickness, not 
simply a side effect. As research attaches ever greater 
importance to inflammation, Yale is considering the 
establishment of an institute devoted exclusively to its 
study, according to Medzhitov and other researchers 
at the school. Understanding the role of inflammation 
in the body at the molecular level could pave the way 
for a new generation of pharmaceuticals and treat-
ments. Because inflammation accompanies nearly 
every illness and disease, the potential for new devel-
opments is enormous. 
“If you are infected, inflammation can even be a 
good thing, helping provide additional signals that 
alert the host to the presence of microbial pathogens 
and recruiting immune cells to the site of infec-
tion. However, you need to turn it off once the infec-
tion is resolved to avoid excessive tissue damage,” 
MacMicking said. “Is there a way to do that? Can I take 
a pill that helps reduce the inflammatory burden?”
the role of cytokines
On a basic level, our understanding of inflammation 
hasn’t changed, Iwasaki said. Inflammation from a 
broken ankle or a bronchial illness, for example, is 
the body’s way of summoning the immune system to 
restore homeostasis. Too much inflammation in and of 
itself can kill by, for example, flooding the lungs with 

















David Hafler says inflammation 
is more than a defense system to 
fight infection—it’s part of how a 
healthy body maintains homeo-
stasis, such as when it prunes 
excess neurons in the developing 
brains of children, or when it oc-
curs in the liver and intestines.
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Now we understand that inflammation can be both 
a cause and an effect, Iwasaki said. Obesity and diabe-
tes are examples, she continued. When people become 
overweight, their fat cells become bigger. Immune 
system cells called macrophages, whose job is to main-
tain homeostasis, sense something is wrong, and they 
deploy disease-fighting small proteins called cytokines 
against the cells, creating inflammation. While the tip-
ping point remains unclear—it appears to vary from 
person to person—the resulting inflammation can lead 
to diabetes and heart disease. Exactly how that happens 
requires further study, said Iwasaki. “We just know that 
if we can block these macrophages from firing, we can 
prevent the disease from happening,” she said. 
Another example is Alzheimer’s disease, Iwasaki 
said. Research indicates that an immune reaction to 
amyloid plaques in the brain may contribute to the 
dreaded illness. According to the model, macrophages 
interpret crystal-like plaques in the brain as foreign 
objects and begin secreting cytokines that attack 
them, which leads to inflammation and destruc-
tion of neurons culminating in dementia. Ultimately, 
inflammation may also play a role in such behaviors as 
depression and suicide, she said.
Hafler, an expert on MS, cites yet another example of 
the double duty performed by inflammatory cytokines. 
His lab compared spinal fluid from healthy medical stu-
dents and patients with MS. Unsurprisingly, the fluid 
from MS patients was inflamed—but so was that of the 
healthy medical students. “We had a very hard time 
telling the difference between MS spinal fluid and nor-
mal spinal fluid,” he said. That’s because cytokines, in 
addition to fighting disease, also help regulate the ner-
vous system in relation to synaptic connections, fluid 
absorption, and other functions, he said. 
keeping the microbiome healthy
There’s another potential source of sickness-inducing 
inflammation: the human gut. Researchers increas-
ingly think that inflammation in the digestive tract 
may be the point of origin of a variety of diseases, 
including neurodegenerative illnesses like Parkinson’s. 
They are also coming to believe that a healthy micro-
biome—the billions of bacteria in the gut that help us 
process food—may be key to avoiding that potentially 
disease-inducing inflammation. 
Noah Palm, PhD ’11, FW ’15, assistant professor of 
immunobiology, and his lab team are probing the con-
nections between the microbiome, inflammation, and 
disease. The microbiome is exquisitely sensitive, Palm 
said. Changes in diet, or even something as seemingly 
benign as living with a dog, significantly alter the 
teeming microbial communities that populate our guts, 
he said. As the Western environment has become more 
antiseptic and most people’s diets contain fewer plants 
and more processed foods, the makeup of our gut 
microbiome has changed, and its diversity has declined 
significantly. At the same time, the incidence of cer-
tain inflammatory illnesses and conditions—allergies, 
obesity, heart disease, diabetes—has exploded. Is there 
a connection?
“In my lab, we are trying to make the transition from 
correlation to causation,” said Palm. He has already 
begun to establish potential causation in certain ill-
nesses, specifically inflammatory bowel disease (IBD). 
He and his lab assistants have found that when micro-
biome material from an IBD sufferer is inserted into 
an otherwise healthy mouse, the mouse will develop a 
disease that looks similar to human IBD. While genetic 
factors may also be involved, these findings indicate 
that particular bacteria may trigger IBD in at least a 
Carla Rothlin wants to know 
about mechanisms that set or 
limit the magnitude of the body’s 
immune response—how a body 
transitions from defense to 
wound repair, and why. 
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subset of patients. Palm’s research has a long way to go, 
but it could ultimately lead to individualized treatments 
designed to maximize microbiome health and stave off 
disease-inducing inflammation. 
a new approach to antibiotic resistance
The expanded understanding of inflammation in the 
gut and how it is induced could also one day address 
one of medicine’s biggest long-term challenges: anti-
biotic resistance. Jorge Galán, PhD, DVM, the Lucille 
P. Markey Professor of Microbial Pathogenesis, pro-
fessor of cell biology, and chair of the Department of 
Microbial Pathogenesis, said his lab studies “in detail” 
intestinal tract diseases—especially salmonellosis. The 
long-held view was that the inflammation resulting 
from Salmonella infection, which makes you sick, was 
caused by the immune system’s attacking the pathogen. 
But “we now know that this is not the case,” Galán said. 
Nutrients are scarce in the gut, Galán added. In 
order to make those nutrients available, Salmonella 
and similar pathogens must induce inflammation. 
That’s not easy because the immune system is tamped 
down in the gut; otherwise recognition of the bacte-
ria in the microbiome would trigger a chronic state 
of inflammation. “Salmonella needs inflammation,” 
Galán said. “Its stomping ground is the gut. Now it’s 
got a problem. It needs inflammation in a place where 
it’s not easy to trigger it.”
Salmonella meets this goal by injecting proteins 
that trigger inflammation, thereby producing the 
nutrients it needs to survive, Galán said. He has on a 
table in his office a clear block containing an image of 
the pathogen’s microinjection device, a gift from his 
students. Most of the time, the resulting inflammation 
isn’t enough to make a person sick because the patho-
gen uses its own mechanisms to turn it off; it’s when 
inflammation gets out of control, which is rare, that 
one develops the classic symptoms of salmonellosis. 
“That is what is so cool about inflammation,” Galán said. 
“There are so many ways to trigger it.”
Galán’s insight potentially creates a new treat-
ment pathway. Instead of killing the pathogen with a 
classic antibiotic, you can try to formulate a targeted 
drug that simply shuts off the microinjection device 
inducing the inflammation, he said. “You gum up the 
bacteria,” Galán said. “You are preventing the bacteria 
from causing disease, which is a totally different con-
cept. Certainly the evolutionary process that leads to 
antibiotic resistance would be slowed significantly.”
The promise of a deeper understanding of inflam-
mation and its roles in sickness and health is signifi-
cant, potentially paving the way for individualized and 
less invasive treatments that work in harmony with 
the body, researchers say. It may well boil down to 
learning how to turn inflammation from on to off. 
“Can we uncouple the beneficial from the harmful 
effects?” MacMicking said. “Find new molecular tar-
gets that mount effective antimicrobial responses but 
avoid the non-collateral damage. Cytokine signaling 
turns on hundreds of genes—is there a way to pick and 
choose downstream host responses we’d like to elicit 
and quieten those we wish to avoid?” MacMicking and 
his fellow Yale researchers are working to find out.  
/yale medicine magazine





















1980s data demonstrated that taking 
aspirin lowered the risk for cardio-
vascular disease. They expanded 
that research to include cancer, and 
determined that aspirin could lower 
mortality there as well, acting as a 
chemopreventative therapy, accord-
ing to Charles Fuchs. 
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Researchers hope that the Colton Center for Autoimmunity at 
Yale will yield results over the next 10 years.
Throughout his career at Yale, Joseph E. Craft, MD, HS ’80, 
FW ’85, has studied autoimmunity, specifically systemic 
lupus erythematosus. Now he’s heading a new project that 
will span the university, encouraging researchers from 
disciplines inside and outside medicine to seek ways to 
move existing knowledge about the more than 80 autoim-
mune diseases from the laboratory to the clinic.
“The goal is to take what we know about autoimmunity 
from our research at Yale and what we have learned from 
others and move those ideas into practical applications,” 
said Craft, the Paul B. Beeson Professor of Medicine 
(Rheumatology) and professor of immunobiology. “Many 
of the proposals will come from immunologists, but by 
no means is it meant to be restricted to experts in auto-
immunity, nor is it meant to be restricted to experts in 
immunology. We want the best ideas: things that may be 
novel, things that may be untried and untested, things 
that may be pie in the sky.”
The Colton Center for Autoimmunity at Yale is an 
outgrowth of an initiative that began at NYU Langone 
Health in 2013. The Judith and Stewart Colton Center for 
Autoimmunity was launched to find new ways of diagnos-
ing and treating autoimmune diseases. Although centered 
at NYU, the program has recruited researchers and clini-
cians throughout the scientific community. Creating a 
satellite center at Yale with Craft in charge was an obvious 
choice—he sits on the NYU center’s advisory board.
The satellite center at Yale will receive funding for up 
to 10 years. In its first year, Craft said, he hopes to fund 
about eight proposals. “The idea is to use funds every year 
to invest in ideas to develop intellectual property,” he 
said. “That’s the first step to getting those into translat-
able initiatives.”
Research proposals from across the university are 
welcome, Craft said. “You don’t have to be an expert 
in autoimmunity to have a good idea. It could be from 
engineering, the Faculty of Arts & Sciences, chemistry,” 
he said, adding that faculty at all levels are encouraged to 
apply. “That only enhances the ability of the program to 
get things done. Biomedical engineering has been very 
successful in thinking about ideas on how to treat cancer. 
If they can bring those ideas to autoimmune disease, that 
would be great.”
An advisory committee of four faculty in immunobiol-
ogy, two academics from outside Yale, and three private 
sector members with experience in technology transfer 
and immune-mediated diseases will review grant appli-
cations. The committee will meet once each year in per-
son and throughout the year in videoconferences.
The application process, Craft said, will be stream-
lined. “We would like to shorten that to a couple of 
months and make the hurdle for applying relatively 
simple,” he said. “Putting the idea on paper ideally would 
be done in a day or two. Our goal is to eliminate the 
bureaucracy and eliminate the timing.”
The new center also fits in with the University Science 
Strategy Commitment (USSC), said Michael C. Crair, PhD, 
the William Ziegler III Professor of Neuroscience, profes-
sor of ophthalmology and visual science, and vice provost 
of research for Yale University. He will serve as an ex 
officio member of the center’s advisory board. The USSC 
will invest in strong areas of science at Yale, specifically 
inflammation, neuroscience, data science, energy science, 
and environment.
“Inflammation is one of the top areas where we’d like 
to build, and autoimmune is one of the pieces within the 
broad area of inflammation,” Crair said. “We want to 
make sure that what we are doing in autoimmunity is 
coordinated with what we are doing in all the inflamma-
tion sciences.” /yale medicine magazine
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Glucose plays a  
complex role in immune 
system health
For followers of popular science news—or of the latest diet 
craze—the term “intermittent fasting” is decidedly trend-
ing. Each new mention of the eating plan brings with it 
more revelations about the health benefits it could offer. 
In the last six months alone, new studies have tied fast-
ing to reduced risk of diabetes, heart disease, and a host of 
chronic inflammatory diseases. Periodic fasting may also 
improve symptoms of multiple sclerosis and inflammatory 
bowel disease. One study found that a 24-hour fast boosts 
regeneration of intestinal stem cells in aging mice. 
But what’s behind all these potential benefits of 
occasionally going without food? Yale research sug-
gests that sugar deprivation gives fasting its many vir-
tues. It may halt or mitigate inflammation that leads 
to or exacerbates numerous illnesses. And it could be 
that each of the potential health benefits of eliminating 
sugar is born of a different mechanism. 
feed a viral infection, starve a bacterial one?
When colleagues Andrew Wang, MD, PhD, HS ’13, 
FW ’17, and Ruslan Medzhitov, PhD, were discussing 
how they feed their kids when they’re sick, they started 
to wonder what was behind the old adage, “Starve a 
fever, feed a cold.”
“All animals—from worms, to flies, to dogs, to us—do 
this. When we get acutely infected, we lose our appetite, 
and people have wondered for a long time why that might 
be,” said Wang, who is an assistant professor of medicine 
(rheumatology) and of immunology. 
The two wanted to find out the potential benefits of 
fasting during an illness. In their 2016 study, published 
in Cell, when they force-fed an animal that was fighting 
listeriosis—a bacterial infection—the animal died. On the 
other hand, feeding an animal battling the flu—a viral 
infection—helped nurse it back to health. 
When the researchers broke the food down into its key 
components—protein, fat, and sugar—they found that 
sugar is the active ingredient. Mice that had viral infec-
tions needed glucose to adapt to the stress brought on by 
antiviral inflammation and to prevent stress-induced cell 
death. In bacterial infections, however, glucose prevented 
ketogenesis, which was necessary to counteract the oxi-
dative stress of antibacterial inflammation. 
Still, Wang said, “As a doctor, I’m hesitant to simply 
say, ‘If you think you have a bacterial infection, starve 
yourself, and if you think it’s viral, don’t.’ ”
And Wang has good reason to hold off doling out 
that advice. The role of glucose in inflammation is far 
more complex. New research suggests that glucose 
deprivation before flu infection may in fact prepare the 
body to fight it. While glucose after flu infection pro-
motes adaptation to inflammation, a November 2019 
study in Science Immunology co-authored by Vishwa 
Deep Dixit, DVM, PhD, the Waldemar Von Zedtwitz 
Professor of Comparative Medicine and professor of 
immunobiology, suggests mice already in ketogenesis 
are better equipped to fight the flu once it hits. 
In the study, mice that were on the high-fat, low-
carbohydrate ketogenic diet when they contracted the 
flu were more likely to survive the illness than those on a 
normal high-carb diet. The extremely low-carb diet, the 
study found, activates a group of T cells in the lungs not 
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previously linked to the immune system’s response to 
influenza. The T cells step up mucus production in airway 
cells and trap the virus.
While the studies point to opposing roles for glucose 
in viral inflammation, they also asked different questions. 
“Our 2016 study,” said Wang, “asks why animals eat 
less when they have the flu. So, we fed them after they 
were infected to see what impact that would have. [This 
new study] asks, ‘If an animal is in a ketotic state, how 
does it affect response to flu infection?’ I think what is 
clear from both studies is that the metabolic state of the 
organism in an infection—before and during, and prob-
ably during recovery—is a critical determinant of the 
organism’s overall outcome in that infection.”
Glucose has a role in parasitic infections, too. Wang  
and Medzhitov explored this relationship in a 2018 
study published in Proceedings of the National 
Academy of Sciences (PNAS). When they blocked gly-
colysis in mice with malaria, the mice didn’t go on to 
develop cerebral malaria. 
The glucose deprivation didn’t make the mice resis-
tant to malaria. In fact, in both groups, parasite burden, 
neuroinflammation, blood-brain barrier permeability, 
and anemia were the same. But, blocking glucose made 
mice more tolerant of the disease. Or maybe, the study 
authors suggest, glycolysis inhibition made the parasites 
themselves less harmful. Either way, fewer micro-
thrombi (tiny blood clots) formed in the brains of those 
mice, preventing the spread of the infection to the brain. 
burn fat, slow aging
Of course, inflammation isn’t only an acute reaction to 
a new infection. Ongoing inflammation is implicated in 
nearly all diseases of aging. If modulating glucose can 
change the course of acute infection, could it also inter-
fere with the lifelong process of aging? 
“Most of the cells in the body run primarily on glu-
cose,” said Dixit. “So, we wanted to know what happens 
when glucose is limited.” The answer sheds more light 
on the various health benefits of fasting and low-carb 
diets like the ketogenic diet. 
When the body doesn’t have glucose for fuel, it burns 
fat for energy. This process occurs in fasting, starvation, 
and in endurance exercise after sugar stores are used up. 
It also happens on a low-carb diet. 
The brain and heart are the biggest consumers of 
the body’s energy. But when the body turns fat into 
long-chain fatty acids, they can’t cross the blood-brain 
barrier. So, the body converts those into short-chain 
fatty acids, specifically a ketone metabolite called beta-
hydroxybutyrate, for the brain’s use. 
When the body runs on fat for fuel, Dixit and his 
team wondered, what happens to immune cell function? 
Macrophages—mobile white blood cells that gather at 
infection sites—run on glucose when they are inflamed. 
“If macrophages aren’t seeing glucose,” Dixit added, 
“but are exposed to alternate fuels instead, how would 
that affect their activation state?” 
What Dixit and his team found was that beta-hydroxy-
butyrate can block an inflammatory protein complex 
called the NLRP3 inflammasome. Now, NLRP3 isn’t all bad. 
It plays an important role in triggering inflammation in 
acute infection. But, Dixit explained, “If it remains chroni-
cally activated, it can lead to multiple chronic diseases and 
it’s implicated in the overall process of aging.” 
When researchers gave beta-hydroxybutyrate to 
NLRP3-inflamed mice, the ketone metabolite blocked the 
inflammasome, and the mice did not go on to develop 
several age-related chronic diseases. 
The findings may help explain why popular diets 
like intermittent fasting and keto bring health benefits 
beyond weight loss. “Because when one is fasting,” 
Dixit said, “the body has to burn fat, and the metabo-
lites that are increased in this process can potentially 
reduce inflammation.” 
just a spoonful of sugar
This deeper understanding of sugar’s role in inflamma-
tion could lay the groundwork for both dietary recom-
mendations and medications that regulate glucose in 
various types of inflammation. 
But that doesn’t mean sugar is all bad. “The appropri-
ate amount of everything is what we require,” said Dixit. 
There’s not one diet that fits all. “Different types of 
inflammation require different things,” said Wang. “So, 
you have a lot of moving parts, and figuring out the 
combination that gives you the best clinical results is 
not trivial.” /yale medicine magazine
Sonya Collins is a frequent contibutor to Yale Medicine Magazine.
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In ancient times physicians extracted from the bark of 
the willow tree a substance—salicylic acid—that reduced 
fevers, inflammation, and pain. By the mid-19th cen-
tury, a French chemist had mixed the acid with acetyl 
chloride to form acetylsalicylic acid, the compound that 
Bayer marketed in 1899 as aspirin. 
Over time aspirin transcended its original uses, and 
by the 1970s and 1980s it was seen as a treatment for 
stroke and heart disease. During the 1980s physicians 
and researchers also saw that it could fight cancer. 
By 1991, they’d found that aspirin lowered the risk of 
colorectal cancer, and subsequent studies linked it to a 
lower risk of other cancers.
Physicians at Yale are helping to figure out whether 
aspirin can keep breast cancer from recurring in 
women who have already gone through surgery, radia-
tion, and chemotherapy.
“There’s an overwhelming amount of data that sug-
gests that taking aspirin may be beneficial, and that 
aspirin is safe enough for the majority of people to take 
daily,” said Neal Fischbach, MD, assistant professor of 
clinical medicine (medical oncology), who’s leading 
the trial at Yale. 
The Aspirin for Breast Cancer (ABC) Trial was 
launched in Boston, sponsored by Brigham and Women’s 
Hospital and Dana-Farber Cancer Institute. The study 
hopes to recruit 3,000 patients between 18 and 70 who 
have had breast cancer, haven’t used aspirin in the past 
month, and whose breast cancer has not recurred. 
Previous studies, said Fischbach, have found a 
reduced risk of recurrent metastatic breast cancer in 
those who take aspirin. “Aspirin might not be prevent-
ing cancer,” he said, “but in those who get cancer, it 
may prevent cancer from spreading.”
Aspirin’s anti-inflammatory properties, Fischbach 
said, inhibit the enzyme cyclooxygenase. “That path-
way is important in production of many inflamma-
tory mediators which have a lot to do with cancer cell 
growth and metastasis,” he said. “For the same reason 
that taking anti-inflammatories may be good to reduce 
joint inflammation and pain, they may also inhibit 
metastatic spread and growth of cancer cells.”
Among aspirin’s drawbacks are the risks of gastro-
intestinal bleeding and hemorrhagic stroke in some 
patients. And, Fischbach said, prior studies just aren’t 
robust enough to recommend aspirin to prevent the 
onset or recurrence of cancer. The only such recommen-
dation to date came in 2015 when the National Cancer 
Institute said that in certain patients, aspirin could pre-
vent colorectal cancer and cardiovascular disease.
Charles Fuchs, MD, MPH, the Richard Sackler and  
Jonathan Sackler Professor of Medicine (Medical 
Oncology), director of Yale Cancer Center, and physi-
cian-in-chief of Smilow Cancer Hospital, traced origi-
nal studies of aspirin and cancer to the 1980s. 
“That is when the data of aspirin and its ability to 
affect cardiovascular risk came to the forefront,” he 
said. “A lot of those studies that were designed to look 
at cardiovascular risk also started to look at cancer risk, 
finding that [aspirin] did reduce cancer mortality.”
Fuchs and colleagues found that aspirin could affect 
the growth of colon cancer cells in the lab. Clinical tri-
als further found a link between taking aspirin regu-
larly and a reduced risk of developing colorectal cancer. 
“That has led a number of policy-making organizations 
to conclude that aspirin is a chemopreventive therapy 
for colon cancer,” he said.
So far Fischbach has recruited 20 patients for the 
breast cancer trial. For five years, half will receive 
aspirin and half will receive a placebo that looks and 
tastes like aspirin. Ideally, Fischbach said, researchers 
would like to see a reduction in cancer recurrence of 
between 25 and 50%.
“We have detected a glimmer that aspirin may be 
good for cancer,” he said, “but we don’t have the really 
robust prospective studies.” /yale medicine magazine
John Curtis is a frequent contributor to Yale Medicine Magazine.
A versatile remedy also a potential treatment for breast cancer. 
by john curtis | otto steininger illustration
Another use for aspirin 
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When a person develops certain autoimmune disorders, 
others often follow in their wake. Figuring out why, and how 
to stop the deterioration, are top priorities for scientists.
Seven years ago, Fatiha began to experience joint pain 
and swelling of her hands. A doctor diagnosed her 
with Sjögren’s syndrome, an autoimmune disease. 
Three years later, the joint pain flared up and was 
accompanied by a severe rash and sudden hair loss. 
Fatiha, 32, who asked for her last name to be withheld, 
could barely walk. The diagnosis was lupus, another 
autoimmune disease.
Still later, she was diagnosed with rheumatoid 
arthritis. In spite of her illnesses, the Trumbull, Conn., 
resident works at a restaurant and is studying com-
puter science at the University of Bridgeport. “I was 
never sick before in my life. Then one day everything 
changed,” she said.
It is not unusual for people who develop one auto-
immune disorder to experience one or more additional 
ones. Figuring out why this happens is challenging for 
clinicians and medical scientists. It’s a tangled web of 
causes and effects.
But experts in the field believe that the knowledge 
they gain from treating such patients combined with 
advances in laboratory research will not only bring 
relief to countless people around the globe but will 
also help scientists better understand the fundamental 
mechanisms of inflammation and the immune system.
While tremendous progress has been made in 
treating some autoimmune disorders, doctors are 
frustrated by the slow progress in treating other 
disorders and in cases where multiple disorders or 
unusual clusters of symptoms occur. “We have to 
understand the mechanisms, especially the immune 
mechanisms. But we also have to understand deeply 
what’s going on with an individual patient. It’s a form 
of precision medicine,” said Insoo Kang, MD, an asso-
ciate professor of medicine (rheumatology) at Yale 
School of Medicine, who is now treating Fatiha.  
“This is what we hope to accomplish over the next five 
to 10 years.” 
Autoimmunity occurs when the immune system 
loses tolerance of the body’s own tissues and be- 
haves as if they are infected with a pathogen. In 
addition, some researchers believe autoimmunity 
may occur when the immune system overreacts to 
a pathogen that has entered the body and attacks 
healthy tissues. 
Typically, autoimmune diseases are treated with 
therapies that depress the immune system—an 
approach that leaves patients vulnerable to viruses, 
bacteria, and other pathogens. “The immune system 
can be protective or pathogenic. It’s the classic meta-
phor—the double-edged sword,” said Jordan Pober, 
MD ’77, PhD ’77, FW ’78, professor of immunobiol-
ogy, the Bayer Professor of Translational Medicine and 
pathology and dermatology.
Untangling the web of 
autoimmune disorders
by steve hamm | otto steininger illustration
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Untangling the web of autoimmune disorders
Some of the more common autoimmune diseases 
include rheumatoid arthritis, which attacks the joints; 
lupus, which affects skin, joints, and kidneys; multiple 
sclerosis, which attacks the nervous system; and 
inflammatory bowel disease. 
Autoimmune diseases are typically caused by muta-
tions in multiple genes, but they can be triggered by 
environmental factors and stress. Inflammation is 
closely associated with autoimmune disorders. Most 
often, it’s a symptom of the disorders, but sometimes 
it’s a trigger. “Immune diseases are very complex. You 
can have the wrong genes but need also the wrong 
microbiome, diet, or environmental factors,” said 
Martin Kriegel, MD, PhD, FW ’06, an associate profes-
sor adjunct of immunobiology.
Tumor necrosis factor (TNF) blockers are being used 
successfully to treat rheumatoid arthritis and other 
autoimmune diseases, including psoriatic arthritis, 
ulcerative colitis, and Crohn’s disease. However, lupus 
and some other diseases are not as well understood. 
People with lupus seem to be particularly susceptible 
to developing additional diseases. 
Researchers believe that a malfunctioning thymus 
may cause some people to have multiple diseases, said 
Kriegel. The thymus is instrumental in the matura-
tion of T lymphocytes (T cells), which are essential for 
fighting pathogens throughout the body. Sometimes, 
because of genetic defects, the T cells aren’t taught how 
to distinguish between pathogens and normal cells. In 
other cases, researchers suspect that checkpoints in 
the lymph nodes and spleen, where immune responses 
are typically launched, are faulty, leading to patients 
having more than one disorder.
The causes and manifestations of autoimmune dis-
eases are so complex that researchers struggle to find 
the best ways to discuss them. Kang describes a “rain-
bow spectrum” of disorders in which causes and effects 
overlap. Often, several gene mutations are shared by 
multiple disorders. Meanwhile, Andrew Wang, MD, 
PhD, HS ’13, FW ’17, assistant professor of medicine 
(rheumatology) and of immunobiology, refers to “con-
stellations” of disease. “If we’re honest with ourselves, 
we recognize that patients with complicated inflamma-
tory diseases can’t all be lumped together and all treated 
the same,” he said.
One of his patients, Lois Walters, a retired postal 
worker in Hamden, Conn., was diagnosed with lupus 
more than a decade ago, yet her symptoms, including 
fatigue, joint pain, and skin rashes, didn’t respond well 
to traditional therapies for lupus. After Wang became 
her clinician four years ago, he tried a different strat-
egy. He recognized that Walters essentially suffered 
from her own personal version of lupus, so he broke 
from conventional therapies and treated each of her 
symptoms separately. It’s working. “This is the best 
I’ve felt in a long time,” said Walters.
Wang believes that a new approach will be required 
to address the complexities of autoimmune disorders. 
Today, many of the successful therapies target immune 
mediators, the signals that immune cells make to tell 
the body there’s a problem. He believes that an alter-
native approach is to target the metabolic programs 
that support the immune cells. 
Wang said research breakthroughs will be essential 
in dealing with these complex illnesses, but so will 
old-fashioned doctoring: “It’s important to be mind-
ful of the particular constellation that your patient 
might have, and it’s important to listen to the patient 
because they’ll tell you what’s wrong with them.” /
yale medicine magazine
Steve Hamm is a frequent contributor to Yale Medicine Magazine.
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Getting warmer: thermoregulation  
and inflammation
The human body has a number of innate responses to infection that include 
heating the affected part of the body, or cooling it down. Yale School of 
Medicine researchers are looking hard at the causes behind both.
The body survives infection in one of two ways: 
resistance or tolerance. In resistance, the body 
uses its resources to mount an all-out war 
against the invading threat and eliminate it. In 
tolerance, rather than spending its resources  
on an attack, the body downshifts into “power-
saver” mode where it rides out the infection. 
During this time, trade-offs are made. Appetite 
loss in sickness, for example, allows the body to 
turn its energy away from food metabolism and 
conserve strength for weathering the illness ahead. 
And body temperature regulation, researchers are 
learning, may also be a key trade-off when surviv-
ing an infection is the body’s top priority.
“The idea of using temperature to modulate 
metabolism and affect immunity is not new, it’s 
just not understood,” said Andrew Wang, MD, 
PhD, HS ’13, FW ’17, assistant professor of medi-
cine (rheumatology) and of immunobiology.
Ancient Egyptians used cryotherapy to treat in-
flammation as early as 2500 BCE. The Edwin Smith 
Papyrus, the oldest known medical text, dated 
3500 BCE, mentions cold therapy multiple times. 
More recent research has begun to disassemble  
the mechanism behind thermoregulation’s immu-
nological success. “It turns out we have to spend a 
considerable amount of energy defending our body 
temperature,” said Wang. Saving that energy could 
help the body enter tolerance mode. 
In a study published in Cell in 2019, Wang and 
his colleagues examined a hormone (growth  
differentiation factor 15 or GDF15) that further 
illuminates the role of metabolic regulation in 
infection tolerance. In mouse models of both bac-
terial and viral sepsis, GDF15 was crucial for sur-
vival—which suggested its value isn’t measured 
by helping the immune system attack a specific 
type of invader. In fact, the hormone is trig-
gered after the body launches an inflammatory 
response. The hormone didn’t reduce pathogen 
levels in mice compared to those in which GDF15 
was blocked, either. 
Researchers suspected that the hormone 
doesn’t help the body resist infection at all. 
Rather, it helps the body tolerate the inflamma-
tion that is necessary to fight it. 
“In an overwhelming infection like sepsis, 
where inflammation becomes a big problem,  
the tolerance approach—rather than resistance 
—can be beneficial,” said Ellen Foxman, MD,  
PhD, FW ’15, assistant professor of laboratory 
medicine and immunobiology. 
The researchers identified physiological 
changes that seemed to shift the mice into 
tolerance mode. For one, GDF15 protected the 
heart from injury in sepsis. It also maintained the 
body’s temperature. Mice in which the hormone 
was blocked suffered hypothermia—a serious 
problem in sepsis patients. 
According to Wang, it will be very important 
to understand how metabolism is controlled to 
increase resistance to disease. Cryopreserva-
tion and other states of suspended animation 
are extreme examples of “power saver” modes 
that confer maximal tolerance to inflammatory 
insults. “Animals that hibernate are extraordi-
narily resistant to stress, trauma, infection, and 
most inflammatory injuries,” said Wang. “There’s 
tremendous interest in seeing how that works.”
—Adrian Bonenberger
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Why most  
heads don’t swell
(from pride or infection)
by christopher hoffman | otto steininger illustration
30 ymm.yale.edu

When it comes to inflammation, not all organs are 
created equal. 
Some—including the brain and the spinal cord 
—are privileged. By that immunologists mean that it 
is very hard to produce inflammation in them. Why? 
Because these organs have very few immune cells. 
It’s difficult for them to get in, and the organs have 
inhibitors that turn off immune cells that do manage 
to gain entry.
“There may be limits to immune invasion and hav-
ing immune cells migrate en masse into them [privi-
leged organs] even though they can enter in small 
numbers as part of ongoing immune surveillance,” 
said John MacMicking, PhD, associate professor of 
microbial pathogenesis and of immunobiology at Yale 
School of Medicine, and a Howard Hughes Medical 
Institute investigator.
On one level, this exclusion of immune cells makes 
sense. The brain and spinal cord, unlike skin or the 
liver, cannot regenerate themselves. Plus, there is 
no backup system for the brain and the spinal cord, 
unlike, for example, the kidneys. Once brain cells 
are gone, they are gone forever. The last thing you 
want is the body’s powerful immune system rampag-
ing through the brain, triggering neuron-destroying 
inflammation as it fights infection. 
“In one sense, cells of the brain like neurons 
may be less well equipped to deal with some of the 
Why most heads don’t swell
Some places in  
the body don’t suffer 
from inflammation  
as a response to  
intrusion.
The brain and  
spinal cord are  
among them.
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toxic products generated during inflammation,” 
MacMicking said. 
The good news is that it’s difficult for diseases to 
get into the brain and the spinal cord. But what hap-
pens when it does? Even worse, what if that disease is 
cancer? This is one of the reasons that treating brain 
carcinoma is so challenging.
As if that isn’t bad enough, doctors face another 
challenge with brain tumors: the blood-brain barrier. 
It’s a thicket of cells that screens out immune cells 
as well as microbes, said Lieping Chen, MD, PhD, the 
United Technologies Corporation Professor in Cancer 
Research and professor of immunobiology, of der-
matology, and of medicine (medical oncology). The 
blood-brain barrier is a good thing in that it keeps 
illness out of the brain, but once again represents 
a double-edged sword, Chen said. The barrier also 
makes getting cancer medication into the brain dif-
ficult, said Chen, the co-leader of cancer immunology 
at Yale Cancer Center.
“There’s a block,” Chen said. “It protects the brain 
from most trouble, but it also makes it more difficult 
to treat brain cancer.”
The blood-brain barrier, however, is not rigid and 
unchanging. It can contract or expand. Researchers 
have learned to trick it to expand, increasing the 
amount of administered medicine that gets through 
to as high as 40%, Chen said. 
Once medicine is inside the brain, clinicians con-
front an additional challenge: keeping inflammation as 
tamped down as possible to avoid damaging delicate 
neurons, Chen said. “If you overdo it a little, you dam-
age the brain,” he said. Understanding and one day 
learning to control inhibitors that block immune cells 
will help make treatments more effective, he said. 
Recent research, meanwhile, has shown that the 
blood-brain barrier is not as absolute as once believed, 
according to MacMicking. “Immune cells do get into 
the brain and look around,” he said. “The idea of 
an impermeable, unforgiving physical structure is 
more of a conceptual model than a functional one.” 
That does allow the cells to initiate inflammatory 
responses to disease, including cancer, he said. 
Spinal cancers, meanwhile, are very rare and inflam-
mation likely plays a role in them as well, MacMicking 
and Chen said. “We know that inflammation, along 
with genetics, is an underlying cause of another central 
nervous system disease, multiple sclerosis [MS],” said 
David Hafler, MD, chair of the Department of Neurology, 
the William S. and Lois Stiles Edgerly Professor of 
Neurology, and professor of immunobiology. An overly 
robust autoimmune response leads to inflammation 
when B cells tell T cells to attack the nervous system, 
Hafler said. This process causes inflammation predomi-
nantly in the white matter of the brain and spinal cord. 
The result is somewhat akin to the insulation being 
stripped from an electrical wire. 
“If you deplete the B cells, you stop the disease,” 
said Hafler, an MS expert. 
As Yale researchers close in on a better under-
standing of inflammation (or a lack thereof) in the 
brain and spinal cord, conditions like MS and other 
nervous system disorders or diseases may soon be 
diseases of the past. /yale medicine magazine
Christopher Hoffman is a contributor to Yale Medicine Magazine.
33Winter 2020

by adrian bonenberger | otto steininger illustration
One doesn’t often think of the intestines when thinking  
about how 3D printing can assist with surgery or medicine. 
John Geibel is looking to change that.
Long considered one of the worst abdominal injuries, 
intestines damaged by trauma or illness are almost 
impossible to heal, and the injuries are fatal under cer-
tain circumstances. New technology may change that: 
3D printing intestines from a subject’s own cells is fast 
approaching commercial viability. And John Geibel, DSc, 
MD, MS, FW ’88, professor of surgery (gastrointestinal), 
of cellular and molecular physiology, vice chair of the 
Department of Surgery, and director of surgical research, 
is at the forefront of efforts to bring 3D-printed intestines 
to market.
“Imagine, God forbid, you’ve been stabbed, or shot, as 
often happens during war, or you develop some condition 
that damages your intestines [radiation treatment, trau-
matic injury, or genetic abnormality that reduces func-
tional intestine]. Soon, we’ll be able to fix that,” said Geibel.
Fixing pieces or lengths of intestine using 3D print-
ing was something Geibel had considered, but it wasn’t 
until he partnered with a company called Organovo 
that he had the equipment to begin trials. Initial test-
ing was promising, with lengths of intestine holding 
up well to volume and pressure, so he decided to push 
the limits, and developed a procedure capable of print-
ing intestines even faster. 
“The key to commercial viability with this process 
is being able to make durable pieces of intestine that 
won’t rupture, in a short enough timeframe that the 
patient can benefit from it quickly. We think we have 
such a procedure,” said Geibel.
Drawn to the intestine partly because of his surgical 
focus on gastroenterology, Geibel said that focusing on 
printing this particular organ provides another advan-
tage to people looking to bring it online quickly as a 
therapeutic option: its relative simplicity.
“The heart has seven cell types with multiple chambers, 
multiple valves. The kidney has 26 different cell types and 
2 million nephrons, not counting connective tissue and 
vasculature. The intestines have seven cell types,” Geibel 
said. “Furthermore, if you implant a piece of intestine 
grown outside the body, that intestine will actually inte-
grate into the rest of the system, so it can absorb nutrients 
and be more than just a length of flexible tubing.”
The absorption of nutrients is one of the key dif-
ficulties for people suffering from diseases, conditions, 
or injuries that affect the intestine. Initial trials have 
been very promising, and 3D-printed intestinal sec-
tions that have been implanted to plug holes or cuts 
made in healthy intestines in a laboratory setting have 
been successful in animal models.
Although there are troubling technical aspects to 
forming viable lengths of intestine, Geibel feels that his 
technique addresses all concerns. Now, he’s working with 
ways to print the intestine faster while also strengthening 
the printed organ so that it can endure the vast amounts 
of liquid, salts, nutrients, and waste products it will be 
expected to carry. The final step will be to test it in people. 
Geibel is eager to advance to this point, and to give people 
who are suffering from life-altering health complications 
hope for a viable replacement that can restore functionality 
to damaged tissue. /yale medicine magazine
Adrian Bonenberger is editor of Yale Medicine Magazine.
A new dimension to 
intestinal surgery
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Exploring the  
frontiers of immunity  
and healing
by katherine l. kraines | otto steininger illustration
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During a 1989 lecture at the Cold Spring Harbor 
Symposium on Quantitative Biology, Yale School of 
Medicine professor Charles Janeway, MD, hypoth-
esized the existence of an innate immune system and 
special receptors on immune cells (currently known 
as toll-like receptors) that trigger the body’s response 
to infection. Janeway’s research later confirmed his 
insights, providing the foundation of future endeav-
ors exploring the intricacies of the human immune 
response. New discoveries continue to reveal an exqui-
sitely tuned immune system in which inflammatory 
responses and healing are initiated and regulated by 
known and unknown mechanisms.
Carla Rothlin, PhD, the Dorys McConnell Duberg 
Professor of Immunobiology and professor of phar-
macology, and co-leader, cancer immunology, Yale 
Cancer Center; and Sourav Ghosh, PhD, associate 
professor of neurology and pharmacology, run Yale’s 
Rothlin Ghosh Laboratory. “We focus on mechanisms 
that set or limit the magnitude of the immune 
response,” said Rothlin, “as well as mechanisms that 
signal the shift from a pathogen-defense mode fol-
lowing successful immune defense to resolution and 
wound repair.” The team is also studying the dif-
ferent types of inflammation that occur as part of 
the immune response and are examining immune 
mechanisms that play a role in the healing process. 
Rothlin and Ghosh’s partnership began as postdoc-
toral fellows at the Salk Institute for Biological Studies, 
where they started to understand the role of three cell 
receptors: Tyro3, Axl, and MerTk, known as the TAM 
receptor tyrosine kinases. While found on other cells, 
these receptors are primarily expressed on the plasma 
membrane of innate immune cells known as macro-
phages and dendritic cells. Continuing their investiga-
tions at Yale, Rothlin and Ghosh found that the TAMs 
are also essential to the healing process.
“Our lab discovered that the TAM receptors serve 
as innate immune checkpoints in regulating the 
magnitude and duration of the immune response by 
working to negatively regulate the response. In other 
words, they operate as brakes on the inflammatory 
response,” Rothlin said. “The goal is to mount an ade-
quate response to fight the bacteria, virus, or parasite 
and not kill you. This process must also regulate the 
immune response to bring the body back to baseline. 
Exploring the frontiers of immunity and healing
Researchers at Yale  
are aware of how 
wounds know to heal. 
Now they want to  
know why.
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The TAM receptors play a pivotal role in the homeo-
static regulation of the immune system.”
The immune or inflammatory response is a finely 
tuned classical feedback loop that begins with toll-
like receptors, located with the TAMs on macrophages, 
reading the presence of a pathogen and activating 
inflammation. The TAM receptors are downstream of 
this positive signal and are activated to tell the toll-like 
receptors to slow down the inflammatory response 
so it is not overdone. Once the pathogen is gone, the 
TAMs identify a type of dead cell associated with the 
transition to resolution of inflammation and induc-
tion of tissue repair, and start the healing process by 
triggering macrophages to eat the cells and produce 
growth factors to make new ones. “What is beautiful 
is the immune system can kill invading pathogens and 
repair the damage after inflammation, and we have 
found that that is contributed to, in part, by the TAM 
receptors,” said Rothlin. 
Together the TAMs serve as negative regulators of 
the immune response, but each receptor has selectiv-
ity of function related to the kind of inflammation that 
occurs. Some TAM receptors function better as brakes 
on a bacterial or viral infection, and others are more 
effective with an allergic response. “Key to under-
standing the role of TAMs is knowing that there are 
different types of inflammation,” Rothlin said. “Being 
infected with a virus is different from mounting an 
allergic response. We discovered that the “T” in TAM—
Tyro3—is a negative regulator of type 2 inflammation, 
which is an allergic response.”
The immune system has an amazing ability to  
recognize invading microorganisms, react, and elimi-
nate them, and to coordinate healing. Yet healing  
is not only dictated by the macrophages, but also by 
the location of the damage. “Different tissues have 
different capacities to recover,” said Rothlin. “Our 
skin and mucosa are in touch with the environment 
and heal better because they are more likely to be 
damaged. However, the brain and heart are not  
that good at healing. You cannot easily make more 
neurons or cardiomyocytes.”
Much is still unknown about the immune mecha-
nisms in autoimmune diseases or cancer. Current 
drugs to treat autoimmune diseases suppress the 
response, but Rothlin noted that the resulting inflam-
matory damage still requires healing. “Autoimmunity 
is complex and is a result of many, many changes 
happening together,” she said. “Targeting the TAM 
receptors might help healing by allowing us to put 
the brakes on chronic inflammation or to release the 
brakes to allow the immune system to persist in a 
sustained way against something like cancer.”
Moving forward, understanding the transition 
from inflammation to tissue repair is going to be very 
important. “We have medications that reduce inflam-
mation, but we have nothing to induce healing,” said 
Rothlin. “Studying what these receptors can do may 
allow us to develop therapeutics that not only limit 
inflammation but also promote tissue repair.” /yale 
medicine magazine
Katherine L. Kraines is a frequent contributor to Yale Medicine 
Magazine.
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Rubor, calor, tumor, 
dolor: Dating from the 
early first century CE, 
these Latin words form 
an incantation that medi-
cal students recite to this 
day. They come from 
the Western world’s first 
known description of 
inflammation, authored 
by one Aulus Cornelius 
Celsus, a Roman who 
observed that the condi-
tion manifests as redness, 
heat, swelling, and pain. 
The Romans weren’t 
the first to mention the 
phenomenon, though. The 
ancient Egyptians wrote 
about pus collections and 
   Inflammation has captured the  
  interest of generations of distinguished  
    clinicians and researchers.
  By Jenny Blair, MD ’04 and Rebecca Frey, PhD ’99
  The intricate history of  
 a long-familiar companion  
   of tissue injury
ulcers, while in the fifth 
century BCE, Hippocrates 
repeatedly brought up 
inflammation in connection 
with such ailments as hem-
orrhoids, superficial skin 
infections, and ulcers. For 
patients with leg wounds, 
the great Greek physician 
made this chatty recom-
mendation (one that sug-
gests he may not have taken 
deep vein thrombosis into 
account): “If a person … at 
first betakes himself to bed, 
in order to promote the cure, 
and never raises his leg, it 
will thus be much less dis-
posed to inflammation, and 
be much sooner well, than 
it would have been if he had 
strolled about during the 
process of healing.”
Hippocrates’ suggested 
herbal treatments included 
boiled mullein, fig and 
olive leaves, and “linseed ...
moistened with the juice  
of strychnos [the source of 
the poison strychnine] or 
of woad, and applied as  
a cataplasm.”
Galen, a Roman medi-
cal authority and personal 
physician to Emperor 
Marcus Aurelius, who was 
revered for over a millen-
nium after his death in 
216 CE, believed inflam-
mation allowed blood to 
escape the arteries. His 
many misconceptions 
were taught until the 
Renaissance. Eventually, 
though, anatomists began 
to glimpse the actual 
inflammatory process 
thanks to the invention of 
the microscope. 
The Dutch medical pro-
fessor Herman Boerhaave 
(1668–1738) peered at 
blood vessels in inflamed 
tissue, decided they were 
too small to conduct blood, 
and proposed that calor 
arises from the blood’s 
generating friction. His 
German-born student 
Hieronymus David Gaubius 
(1705–1780), whom his-
tory will also remember as 
the discoverer of menthol, 
correctly linked inflam-
mation to coagulation. 
The Scottish surgeon 
John Hunter (1728–1793), 
another careful observer, 
wrote a book (published by 
a colleague in 1794) com-
prising detailed discus-
sions of inflammation and 
its connections to such col-
orful ailments as “putrid  
and jail-distempers,” gout, 
and ringworm. 
Henri Dutrochet, a 
French botanist and physi-
ologist, watched white cells 
escaping through vessel 
walls in 1824; and Rudolf 
Wagner, a German anato-
mist, described leukocyte 
rolling in 1839—processes 
by which inflammation 
delivers cells to the site 
of injured tissue. In 1867, 
the pathologist Julius 
Cohnheim realized that 
changes in vessel walls 
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capsule
allow white cells to cross, 
alliteratively describing 
a typical cell as a “color-
less, matte-shining, con-
tractile corpuscle.” Ilya 
Ilyich Metchnikoff in 1893 
described different white 
cell types and observed 
that the engulfment of 
harmful agents by amoeba-
like phagocyte cells is 
central to the process of 
inflammation. He shared 
the 1908 Nobel Prize in 
Physiology or Medicine for 
his work on immunity.
In an irony that per-
sists today, battlefield 
experience increased the 
West’s understanding of 
infection, inflammation, 
and healing. Surgeons in 
the Roman army—the first 
army to have a dedicated 
medical corps—empha-
sized the importance of 
keeping surgical instru-
ments clean and promptly 
evacuating wounded men. 
In 16th-century France, 
an era when gunpowder 
weapons complicated trau-
matic inflammation and 
even minor wounds could 
lead to tetanus, Ambroise 
Paré challenged prevail-
ing Galenic notions after 
engaging in an accidental 
experiment. One day in 
1537, after running out of 
the usual gunshot-wound 
dressing—excruciating and 
injurious boiling oil—Paré 
applied a soothing oint-
ment to such wounds, to 
laesa, or loss of function  
of the affected body part 
—by Rudolf Virchow, the 
19th-century German 
pathologist. (Legend has 
long held that Galen did 
so, but in his 1991 book 
The Healing Hand:  
Man and Wound in the 
Ancient World, physician-
historian Guido Majno 
argues persuasively that  
it was Virchow.) Far ahead 
of his time, Virchow also 
linked inflammation to 
atherosclerosis. 
The 20th-century saw 
repeated milestones in the 
study of inflammation, and 
far better effect. He went 
on to be known as the 
father of military surgery. 
Dominique Jean Larrey, 
a surgeon in Napoleon’s 
army and the inventor of 
field triage, broke with a 
tradition of delayed ampu-
tation by performing it 
promptly to reduce the risk 
of inflammation and infec-
tion; in 1809 he amputated 
the shattered leg of one 
of Napoleon’s marshals 
in less than two minutes. 
His technique for treat-
ing abdominal gunshot 
wounds also avoided the 
inflammatory complica-
tions that had beset those 
of his predecessors. Larrey 
also insisted on retrieving 
wounded men and tend-
ing to them behind the 
front, reviving the long-
defunct Roman practice. 
Trailblazing, trousers-
wearing American Civil 
War surgeon Mary Walker 
clashed with her colleagues 
against the overuse of 
amputation, arguing that 
it is often unnecessary. 
These surgeons contrib-
uted to a move away from 
indiscriminate amputation 
of wounded limbs on the 
grounds that the prac-
tice increases the risk of 
inflammation rather than 
lowering it.
In the 19th-century, to 
the classical list of inflam-
mation’s four signs was 
added a fifth sign—functio 
we now understand the 
basic steps of the process. 
Blood vessels dilate, lead-
ing to redness and heat; 
they become leaky, causing 
swelling as fluid and cells 
cross their walls; and pain 
arises from pain receptors 
in the inflamed tissue. 
Today, researchers 
believe subtle, chronic 
inflammation contrib-
utes to many diseases 
of modernity, including 
heart disease, obesity, 
depression, cancer, and 
even dementia. Even 
the gradual attenua-
tion of bodily functions 
that accompanies grow-
ing older is thought to 
be powered in part by 
inflammation, a process 
called “inflamm-aging.” 
Inflammation was one 
of the first symptoms 
of injury or infection 
noticed by ancients.  
As science has ad-
vanced over the years, 
doctors have come to 
understand far more 
about the mechanisms 
governing how the 
body inflames, and un-
der which conditions. 
Some of Peter Parker’s  
patients in 19th-
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growing up in la rioja, spain—wine country—Judit 
Jimenez Sainz, PhD, was surrounded by people involved 
with the production of its famous red. Her grandfather 
made wine; both of her uncles own vineyards; and as a 
little girl, she picked grapes from the vines. 
where she took her PhD. She 
also spent a year in the United 
Kingdom at University College 
London, broadening her 
research capabilities and her 
professional network. But her 
journey was just beginning.
“I am a biochemist and 
molecular biologist who focuses 
on breast and ovarian cancer 
in women, and ways to iden-
tify, prevent, and (I hope) cure 
it,” said Jimenez Sainz. “I ended 
up in New Haven because 
that’s where I had the best 
feeling about my PI [principal 
investigator].” 
Jimenez Sainz had heard of 
Yale—“Of course, everybody 
knows about the Ivy League in 
Europe”—but hadn’t realized it 
is in New Haven, Conn.—a place 
unfamiliar to her. Originally set 
on working in a big city “like 
Boston or New York,” Jimenez 
Sainz was ultimately drawn 
to the research possibilities at 
Yale, the academic culture, and 
sense of optimism she felt about 
her lab. Now, she is an associ-
ate research scientist with the 
Jensen Lab in the Department of 
Therapeutic Radiology.
It didn’t take long for Jimenez 
Sainz to adapt to New Haven. 
And while she was adjusting 
to the United States, she dove 
headfirst into her research 
and also into the commu-
nity, becoming involved with 
the E-visibility program (of 
which she is now director) and 
Españoles Científicos en USA 
(ECUSA: Spanish Scientists in 
the United States). She is also a 
In high school, though, Jimenez 
Sainz decided on a path a long 
way from viticulture. Her teach-
ers, glimpsing a talent for sci-
ence and research, advised her 
to explore those fields. And 
although her first thought as a 
young woman was that science 
is for men, she trusted her men-
tors. When it came time for col-
lege, they encouraged her  
to find the best institution to 
feed her curiosity. 
“I’m very grateful to my 
teachers for helping me chal-
lenge myself,” said Jimenez 
Sainz. “They were instrumen-
tal to pushing me to seek out 
opportunities in research.” 
Jimenez Sainz decided to study 
at the University of Valencia, 
ymm.yale.edu42
faces
Judit Jimenez Sainz’s 
research brought her 
from her native Spain 
to England, and now, 
to the United States. 
Her advocacy for 
gender equality in  
science and medicine 
will bring her to  
Antarctica this fall.
men. I have a lot of catching up 
to do with leadership training.”
Hence the culminating 
three-week trip to Antarctica. 
“Until 1969, women were for-
bidden from Antarctica. Not 
because of any laws—there is 
no government in Antarctica. 
Just because with a very small 
number of exceptions, they 
weren’t brought on scientific 
strong advocate of women in sci-
ence, which is how she came to 
participate in a program called 
Homeward Bound that will send 
her to spend three weeks in 
Antarctica later this year.
“Homeward Bound is an inter-
national leadership, scientific, 
and visibility initiative that aims 
to bring 1,000 STEMM [science, 
technology, engineering, math, 
and medicine] women across the 
globe in 10 years,” said Jimenez 
Sainz. Part of the cohort HB5, 
Jimenez Sainz discusses the pro-
gram and fundraising for it on 
her webpage. 
Why leadership? “Just like I 
had to learn how to do experi-
ments properly, I need to learn 
more about the craft of leader-
ship,” she said. “I hate to say it, 
but growing up, it didn’t even 
occur to me that I could be a 
scientist, let alone a department 
head or a dean. I thought, to be 






















from Yale School of 
Medicine, Howard Koh 
served as Commission-
er of Public Health for 
the Commonwealth 
of Massachusetts and 
the Assistant Secre-
tary for the United 
States Department of 
Health and Human  
Services under Presi-
dent Barack Obama. 
He shares some of his 
insights into how to 
achieve lasting success 
in life.
For more on lasting  
success, visit ymm.yale.
edu/success
expeditions or military opera-
tions. The prohibition was, from 
a certain perspective, self-
imposed: women thought that it 
would be impossible for them to 
go to Antarctica, that they had 
nothing to contribute to such an 
expedition. Homeward Bound 
helps foster leadership, and self-
starting is part of that,” said 
Jimenez Sainz. “I’m looking for-
ward to what the future holds.”
—Adrian Bonenberger 
»
Paying it back:  
Kristina Brown’s quest
Chronic disability casts a 
shadow over the lives of people 
who live with it. One can never 
be sure when the condition or 
illness will flare up or be perma-
nently exacerbated. Even when 
times are good, it’s difficult to 
focus fully on long-term projects 
like career or education, know-
ing that a setback could be just 
around the corner.
Kristina Brown’s mother’s 
multiple sclerosis was under 
control for much of Brown’s 
childhood, and her family was 
financially healthy. That changed 
when Brown was a teenager 
and her mother’s disease wors-
ened to a debilitating level. Her 
mother’s need for home care 
required Brown to devote sig-
nificant time each day when she 
was still just in high school. Her 
parents divorced when Brown 
was in college, further reducing 
resources available for care. Only 
Brown and one of her sisters 
acting as caregivers kept their 
mother alive. 
So it was that when Brown 
was accepted to Yale School 
of Medicine (YSM), normally 
among the happiest days in a 
young student’s life, she was 
faced instead with a terrible 
choice: continue caring for her 
mother at home, foregoing a 
career in medicine, or pursue 
her dream and accept major 
financial risk and indebtedness 
by taking out student loans  
to not only pay for her educa-
tion but also for the care of  
her mother.
Luckily for Brown, for YSM, 
and for the United States, she 
took the latter path. Now a 
fourth-year student at YSM, she 
has a lot to say on the subject of 
equitable treatment of individu-
als with disabilities as well as 
fair compensation for caregiv-
ers. “We have a health system 
that is full of gaps, where entire 
groups of people are routinely 
overlooked,” said Brown. “And 
we have an economic system 
where caregivers go into debt 
and make unthinkable sacri-
fices taking care of loved ones. 
It doesn’t have to be this way.” 
The gap to which she refers, 
and which is referenced in an 
op-ed she published in the 
Washington Post, has to do with 
health insurance coverage. Her 
mother made too much money 
to qualify for Medicaid, a health 
care system that covers the 
poor, but her private insurance 
did not cover home health care 
for such daily needs as bathing 
and personal hygiene. And in 
any case, private insurance did 
not leave Brown’s mother with 
enough money to pay for home 
care along with a mortgage and 
all other expenses. Medicare, 
the health system that covers 
elderly patients, kicks in only 
when one reaches 65. What is a 
middle-aged, middle-class dis-
abled person to do?
Brown wrote about the 
dilemma. Titled “My family 
faces an impossible choice: car-
ing for our mom, or building our 
future,” the article took months 
of drafting and energy, as well 
as some assistance from a writ-
ing mentor, Anna Reisman, MD. 
When the Washington Post 
published the article, it went 
viral, and Brown received an 
invitation to testify in front of 
Congress a week later. She did so 
at a hearing in honor of National 
Alzheimer’s Disease Awareness 
Month and National Family 
Caregivers Month. “It was a 
great honor to get to speak in 
front of Congress,” she said.
Hopeful about the poten-
tial for future reforms, Brown 
said that extended disability 
is something that everyone 
should care about. “If you’re in 
the middle class, it can happen 
to you,” she said. “Imagine your 
son or daughter donating hours 
of their lives to your care out  
of financial necessity. That’s the 
reality many Americans live 
with today.”
The article has had two out-
comes that give Brown great 
hope: first, responses by people 
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in her position who have said 
the op-ed inspired them and 
made them realize they aren’t 
alone; and second, opportuni-
ties to cover expenses while 
she’s still in New Haven and 
unable to give her mother the 
necessary assistance.
One such source of assistance 
is a GoFundMe page that Brown 
set up with the goal of raising 
$80,000 for home care for her 
mother. As of this writing, she 
has raised $14,339 of the total 
needed—a not-inconsiderable 
sum, though short of her goal. 
“I thought about leaving medi-
cal school before the piece came 
out, to return to caregiving for 
my mother,” said Brown. “I had 
explored and applied for every 
option for financial assistance, 
and without any forthcoming, 
I felt trapped and desperate. The 
community has responded so 
well, it’s amazing.”
Brown’s next stop will 
be residency at UCLA, in 
Medicine-Pediatrics. She hopes 
this will help her to grow as an 
advocate for individuals who 
through no fault of their own 
lack voices; those with disabili-
ties; and those systemically dis-





















Kristina Brown published 
an op-ed with the Wash-
ington Post in 2019 about 
the difficulty of being a 
caregiver for her mother, 
who suffers from MS. The 
piece resonated deeply 
with other Americans, 
and was widely read and 
shared, landing Brown 
an opportunity to testify 
in front of Congress the 
following week. Now she’s 
carrying that advocacy 
work forward with her.
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   The machinery  
  of immune systems 
Chemical interactions 
form an important part 
of the antigen-antibody 
relationship. 
When Craft was a first-
year medical student, he 
helped care for a patient 
with systemic lupus 
erythematosus (SLE), an 
autoimmune disease that 
has no cure as of 2020. 
Craft decided then that 
he wanted to understand 
immunology through 
lupus. “It was a very 
mysterious disease at the 
time,” Craft said. “It still 
is, but we know a lot more 
about how it works.” 
Since he arrived at  
Yale in 1980, Craft’s 
immunology research 
has focused on how lupus 
develops, along with  
different aspects of the 
immune system’s response 
to foreign pathogens and  
vaccines. He directs the 
Investigative Medicine 
Program for physicians 
who earn a PhD while gain-
ing experience in the lab  
or in-patient research. In 
2004, he won Yale’s presti-
gious Charles W. Bohmfalk 
Prize for teaching in the 
basic sciences and is a 
fellow of the American 
Association for the 
Advancement of Science. 
Yale Medicine Magazine 
discussed antibodies and 
inflammation with Craft, 
as well as follicular B helper 
T cells (TFH), which his 
laboratory also studies, and 
which could play a future 




F ROM A YOU NG AGE , Joseph Craft, MD, FW ’85, the Paul B. 
Beeson Professor of Medicine (Rheumatology) and professor of 
immunobiology, adopted a problem-solving approach to chores 
on his childhood 300-acre farm in rural North Carolina. If a 
piece of farm machinery shuddered to a stop in the middle of a 
cornfield, Craft inspected every piston, rod, and washer in the 
engine to diagnose the problem. If one of his calves fell ill, he 
needed to find out why. “You develop a curiosity about all kinds 
of things,” Craft said. 
{ To nominate a subject for Q&A, contactYale Medicine Magazine, 1 Church Street, Suite 300, New Haven, CT 06510, or email ymm@yale.edu.
In college, Craft honed 
his curiosity in chem-
istry, which laid the 
groundwork for a career 
devoted to understand-
ing the immune 
system—particularly 
antibodies. Antibodies are 
proteins formed to bind 
to and attack antigens—
structures located on the 
surface of invading viruses, 
bacteria, and other foreign 
molecules that can trig-
ger an immune response. 






Lupus is an autoimmune 
disease. Briefly, what’s 
going on in the immune 
system when it develops?  
Our immune system 
produces antibodies, 
proteins that circulate 
in the blood, that pro-
tect us against infec-
tions. The cells that 
make antibodies are 
called B lymphocytes. 
When you get a flu 
vaccine, for example, 
the vaccine initiates 
production of antibod-
ies by B lymphocytes, 
which lead to protection 
against flu infection. 
This is a well-regulated 
process, and vac-
cines are quite safe. In 
patients with lupus, 
however, the immune 
system is not regulated 
properly, and patients 
with lupus develop 
antibodies against DNA 
and RNA, which are in 
every cell. Antibodies 
directed against compo-
nents of one’s own cells 
are called autoantibod-
ies. Autoantibodies bind 
to the individual’s tis-
sues, damaging organs, 
especially the skin, 
joints, and kidneys in 
lupus. As a consequence, 
the majority of patients 
with lupus have skin 
and joint inflamma-
tion, and about half of 
patients will have kid-
ney disease. 
survive, as well as how 
they help B lymphocytes 
make antibodies. We’ve 
identified how they are 
activated and new ways 
to characterize them. 
In lupus, T follicular 
helper cells are also 
required for produc-
tion of tissue-damaging 
autoantibodies. 
Would TFH cells be a good 
target for a potential new 
drug for lupus? We have 
shown that targeting  
TFH cells could help 
symptoms of lupus, but 
we are trying to deter-
mine which mechanism 
of TFH cells to target, and 
how to do this effectively 
and safely. 
What stands out in your 
more than 30 years here 
at Yale? Yale is a special 
place to do research and 
care for patients because 
of the dedication, exper-
tise, and intellect of 
the students, staff, and 
faculty. I’ve learned so 
much from these col-
leagues, shaping how I 
care for patients and do 
science. What is most 
impressive are the stu-
dents and trainees. Their 
intellect, capacity for 
work, their curiosity—
it’s just mind-boggling. 
One can’t help but make 
contributions in an 
environment like this.
How does inflammation 
figure into this?  
Autoimmunity is a 
response of the immune 
system against itself. If 
not properly regulated, 
autoimmune attacks lead 
to tissue inflammation 
and ultimately damage, 
if not properly treated. 
How do follicular B helper 
T (TFH) cells figure into this 
process? We are try-
ing to understand how 
TFH cells contribute to 
inflammation in lupus 
and what drives chronic 
inflammation. TFH cells 
largely function in 
your spleen and lymph 
nodes. B lymphocytes’ 
production of protec-
tive antibodies, after 
flu shots for example, 
absolutely requires help 
from a second T helper 
lymphocyte. The lat-
ter are called follicular 
helper T cells, as they 
reside in special areas 
of the spleen and lymph 
nodes, the follicles 
where B lymphocytes 
also reside. An anal-
ogy would be if you are 
lifting a sofa, you can 
lift one end, but you’ll 
need help with the other 
end. Now we are trying 
to understand the basic 
biology of TFH cells—



















  Permission  
 to feel
   By Cathy Shufro
Our vocabulary for emo-
tion is impoverished. We’re 
stressed or we’re good; we’re 
bummed or we’re okay. The 
meagerness of this lexicon 
tells us something about 
ourselves, according to 
psychologist Marc Brackett, 
PhD: It shows how hazily we 
perceive our feelings. 
And physicians on aver-
age may be particularly 
undiscerning. It’s an occu-
pational hazard: As doctors 
rush from patient to patient, 
they can’t take time to reflect 
on feelings. And when they 
witness the suffering caused 
by illness and death, one way 
they cope is to drive emo-
tions underground.
Except suppression doesn’t 
work, said Brackett, direc-
tor of the Yale Center for 
Emotional Intelligence and 
professor in the Child Study 
Center. When doctors habitu-
ally suppress their feelings, 
they burn out, even get sick. 
And patients view emotionally 
blank doctors as heartless. On 
the other hand, patients don’t 
benefit from seeing their phy-
sicians sobbing uncontrollably. 
“You don’t want other people 
to think they need to take 
care of you,” said Brackett.
In his new book, 
Permission to Feel: Unlocking 
the Power of Emotions to 
Help Our Kids, Ourselves, 
and Our Society Thrive, 
Brackett helps readers find an 
emotional equilibrium, or a 
“best self.” That self is at once 
collected and compassion-
ate, Brackett writes. Using 
stories of deprivation and 
distress from his own child-
hood, Brackett provides a 
method for realizing that best 
self: recognizing and regulat-
ing emotions, and learning to 
express feelings judiciously 
in accord with the situation. 
Acknowledging feelings, he 
said, “prevents emotions from 
having undue influence over 
our actions.”
The best self shows sym-
pathy not only for others 
but also compassion for the 
self. For instance, when a 
patient dies, a doctor might 
tell himself or herself, “You 
really did everything pos-
sible to support this person.” 
Brackett also recommends 
giving priority to self-care. 
“My workouts and yoga ses-
sions are in my calendar,” he 
said. Recently, he’s begun 
using meetings to take walks. 
Groups of colleagues will 
also fare better if they share 
feelings. For instance, at a 
casino where Brackett served 
as a consultant, workers 
quit frequently because they 
were worn down by being 
around gamblers who were 
drunk or angry about losing 
money. Scheduling time for 
the workers to talk over the 
emotional toll of their work 
reduced turnover. Brackett 
suggests that group medi-
cal practices schedule time 
for meetings whose sole aim 
is to “to provide time and 
space to just process.”
Checking in with one’s 
emotions also prevents a 
reaction to one situation from 
coloring the next interaction. 
“If you name it, you can tame 
it,” Brackett said. “Once you 
attribute that emotion to its 
source, it no longer will have 
a subconscious influence on 
how you interact in that sec-
ond setting.” 
Understanding the emo-
tions of another person, he 
writes, “requires the use 
of our storytelling ability, 
perspective-taking skills, 
and pattern-seeking to piece 
together the concatenation 
of feelings and events that 
led to the current situation. 
It begins with being an emo-
tion scientist, not a judge.”
Just as understanding 
emotions requires listening, 
so does finding the best way 
to help someone in distress. 
Brackett suggests asking such 
open-ended questions as, 
“What do you need right now? 
How can I support you?”
Brackett teaches a 
course at Yale College called 
Emotional Intelligence that 
draws hundreds of students. 
Sometimes a student will tell 
him, “I didn’t need emotional 
intelligence to get into Yale, so 
why is it so important?” And 
doctors have said, “I’ve got-
ten here without those skills.” 
Brackett’s answer: “ ‘What 
about the quality of your rela-
tionships? What about your 
physical health? What about 
your mental health?’ It’s a 
narrow definition of success.” 
Real flourishing, he argues, for 
the individual and for society, 
will arise when we give our-
selves—and others—permis-



























{Send notices of new books toYale Medicine Magazine, 1 Church Street, Suite 300, New Haven, CT 06510, or email ymm@yale.edu.
book review
ON ON E OF T H E C OL DE R E V E N I NG S of an unusually warm winter, dozens of faculty, faculty  
emeriti, and department chairs gathered in Yale School of Medicine (YSM)’s Medical Historical 
Library to shake hands with the new dean and raise their glasses to the former dean.
The affair was comfortable and familiar, with Nancy J. Brown, MD, the Jean and David W. 
Wallace Dean of Medicine and C.N.H. Long Professor of Internal Medicine, mingling and chatting 
with her new colleagues. She said she begins her journey as dean with YSM in “an incredible place, 
due largely to the leadership of Bob Alpern.” Robert J. Alpern, MD, Ensign Professor of Medicine 
and professor of cellular and molecular physiology, partook in the festivities, basking in the glow of 
15 years’ efforts successfully handed over to a capable and competent successor. With that, one era 
was over, and another began.
—Adrian Bonenberger
 Hail and Farewell
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end note
